1Gertz MA,,Ghobrial I,Luc-Harousseau J.Multiple myeloma:biology,standard therapy,and transplant therapy〔J〕[].Biology of Blood and Marrow Transplantation.2008
2Vesole DH,Zhang L,Flomenberg N,et al.A Phase II trial of autolo-gous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma:an analysis of Eastern Cooperative Oncology Group ECOG E4A98and E1A97〔J〕[].Biology of Blood and Marrow Transplantation.2009
3Kumar A,Kharfan-Dabaja MA,Glasmacher A,et al.Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma:a systematic reviewand meta-analysis〔J〕[].Journal of the National Cancer Institute.2009
4NCCN Multiple Myeloma Panel.NCCN clinical practice guideline in oncology:multiple myeloma national comprehensive cancer〔M〕[]..2009
5Gahrton G,,Bj rkstrand B.Allogeneic transplantation in multiple mye-loma〔J〕[].Haematologica.2008
6Rosenblatt J,Avigan D.Cellular immunotherapy for multiple myeloma〔J〕[].Bailliere s Best Practice and Research Clinical Haematology.2008
7Blad J,Rosi ol L.Advances in therapy of multiple myeloma〔J〕[].Current Opinion in Oncology.2008
9Jagannath S,Barlogie B,Berenson JR,et al.Updated survival analyses after prolonged follow-up of the phase2,multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma〔J〕[].British Journal of Haematology.2008
10Lee SJ,Richardson PG,Sonneveld P,et al.Bortezomib is associated with better health-related quality of life than high-dose dexametha-sone in patients with relapsed multiple myeloma:results from the A-PEX study〔J〕[].British Journal of Haematology.2008
10Moreau P, Misbahi R, Milpied N, et al. Long-term results(12 years) of high-dose therapy in 127 patients with de no-vo multiple myeloma[ J]. Leukemia,2002,16(9) :1 838 -1 843.
